Aug 15, 2024 | Food and Drug Administration (FDA), MDMA (ecstasy), Psychedelic drugs
The potential for psychedelic drugs to serve legitimate medical purposes has become a growing topic of discussion. On August 9, the Food and Drug Administration rejected midomafetamine (MDMA), better known as ecstasy, as a treatment for post-traumatic stress disorder....
Aug 5, 2024 | Biosimilar, Cost Savings, Food and Drug Administration (FDA), Humalog, Opinions, Savings
From a STAT opinion piece by Juliana M. Reed, executive director of the Biosimilars Forum: “Biologic medicines are some of the most important drugs in the world. They are also among the most expensive. Biosimilars are FDA-approved treatments that are similar to...
